<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041235</url>
  </required_header>
  <id_info>
    <org_study_id>ATI1123-101</org_study_id>
    <nct_id>NCT01041235</nct_id>
  </id_info>
  <brief_title>Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered ATI-1123, a Liposomal Docetaxel Formulation, on an Every 3 Week Schedule, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azaya Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azaya Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety profile, including the maximum tolerated&#xD;
      dose (MTD), of ATI-1123 a liposomal formulation of docetaxel, in the treatment of cancer&#xD;
      patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The majority of advanced stage human cancers are fatal if not treated promptly and&#xD;
      aggressively. Standard treatments include chemotherapy, radiation therapy and surgery.&#xD;
      Docetaxel, the active ingredient in ATI-1123 and the FDA approved drug Taxotere, is a&#xD;
      chemotherapy given by IV to patients to treat various types of cancers.&#xD;
&#xD;
      Docetaxel is a poorly water soluble semi-synthetic taxane analog commonly used in the&#xD;
      treatment of a variety of solid tumors including non-small cell lung, prostate, breast,&#xD;
      gastric and head and neck cancer. Because of its poor water solubility it is formulated with&#xD;
      co-solvents that can potentially contribute to treatment related adverse events such as&#xD;
      hypersensitivity. Current taxane formulations often complicate drug delivery and can alter&#xD;
      both pharmacokinetic and toxicity profiles.&#xD;
&#xD;
      Results from nonclinical evaluations show that ATI-1123 retains the antineoplastic activity&#xD;
      of docetaxel while removing the need for unwanted solvents like Tween 80. The administration&#xD;
      of ATI-1123 versus other docetaxel chemotherapy formulations is expected to reduce&#xD;
      hypersensitivity reactions (redness, swelling, itching at the infusion site), eliminate the&#xD;
      requirement for premedications, have a broader therapeutic index, and enhance systemic&#xD;
      docetaxel exposure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the (MTD) and (DLTs) of ATI-1123 administered every 3 weeks, over a range of doses in patients with advanced solid tumors.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the dose recommended for future phase II studies with ATI-1123.</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish the pharmacokinetics of intravenously administered ATI-1123.</measure>
    <time_frame>Cycle 1 (various time points within the cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To observe patients for any evidence of antitumor activity of ATI-1123 by objective radiographic assessment.</measure>
    <time_frame>Every 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>ATI-1123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-1123 (active drug = docetaxel)</intervention_name>
    <description>Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV</description>
    <arm_group_label>ATI-1123</arm_group_label>
    <other_name>ATI-1123</other_name>
    <other_name>ATI1123</other_name>
    <other_name>Docetaxel</other_name>
    <other_name>Docetaxol</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and sign a written IRB-approved informed consent form.&#xD;
&#xD;
          -  Have a histologically confirmed solid tumor.&#xD;
&#xD;
          -  Have progressive disease following standard/approved chemotherapy or have no&#xD;
             appropriate alternative therapy available.&#xD;
&#xD;
          -  Have one or more tumors measurable or evaluable as outlined by modified RECIST or&#xD;
             evaluable by CT or MRI scan.&#xD;
&#xD;
          -  Have an ECOG performance status of ≤ 2.&#xD;
&#xD;
          -  Have a life expectancy of at least 3 months.&#xD;
&#xD;
          -  Be ≥ 18 years old.&#xD;
&#xD;
          -  Have a negative pregnancy test (if female of childbearing potential)&#xD;
&#xD;
          -  Demonstrate acceptable hepatic function:&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN&#xD;
&#xD;
          -  Demonstrate acceptable renal function:&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2&#xD;
             for patients with creatinine levels above institutional normal (Calculated according&#xD;
             to the Cockroft and Gault formula)&#xD;
&#xD;
          -  Demonstrate acceptable hematologic status:&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1500/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3 (measured within 72 hours prior to initial dose)&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Demonstrate acceptable coagulation status:&#xD;
&#xD;
          -  PT or INR within 1.5x ULN&#xD;
&#xD;
          -  PTT within 1.5x ULN&#xD;
&#xD;
          -  Have recovered from prior treatments (eg, surgery, radiation, chemotherapy,&#xD;
             investigational therapies) sufficiently prior to Day 1 so that, in the opinion of the&#xD;
             Investigator and/or Medical Monitor, the protocol objectives would not be compromised.&#xD;
&#xD;
          -  Agree to use an effective contraceptive method (hormonal or barrier method; or&#xD;
             abstinence) for the duration of the study and for 30 days after the last dose (for men&#xD;
             and women of child-producing potential).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have New York Heart Association Class III or IV cardiac disease, myocardial infarction&#xD;
             within the past 6 months prior to Day 1, unstable arrhythmia, or evidence of ischemia&#xD;
             on electrocardiogram (ECG).&#xD;
&#xD;
          -  Have a seizure disorder requiring anticonvulsant therapy.&#xD;
&#xD;
          -  Have active CNS metastasis. Patients with a history of CNS metastases will be eligible&#xD;
             if they have been treated and are stable without symptoms for 4 weeks after completion&#xD;
             of treatment, with image documentation required, and must be either off steroids or on&#xD;
             stable dose of steroids for ≥ 1 week prior to enrollment.&#xD;
&#xD;
          -  Have severe, chronic obstructive pulmonary disease with hypoxemia.&#xD;
&#xD;
          -  Have active, uncontrolled bacterial, viral, or fungal infections requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          -  Are pregnant or nursing.&#xD;
&#xD;
          -  Have undergone radiation therapy, surgery, chemotherapy, or investigational therapy&#xD;
             within 28 days prior to study entry (6 weeks for nitrosoureas or Mitomycin C).&#xD;
&#xD;
          -  Are unwilling or unable to comply with procedures required in this protocol.&#xD;
&#xD;
          -  Have a known history of infection with HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Have a serious nonmalignant disease that, in the opinion of the Investigator and/or&#xD;
             the Medical Monitor, could compromise protocol objectives.&#xD;
&#xD;
          -  Are currently receiving any other investigational agent.&#xD;
&#xD;
          -  Have exhibited allergic reactions to docetaxel, or a similar structural compound,&#xD;
             biological agent, or formulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony W Tolcher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Texas Accelerated Research Therapeutics (START)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Nemunaitis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Crowley Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon M Rogers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azaya Therapeutics, Inc (Medical Monitor)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers (MCCRC)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center (CTRC)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.marycrowley.org</url>
    <description>Mary Crowley Medical Research Center website</description>
  </link>
  <link>
    <url>http://www.azayatherapeutics.com/index.php</url>
    <description>Azaya (sponsor) website</description>
  </link>
  <link>
    <url>http://www.uthscsa.edu</url>
    <description>Cancer Therapty and Research Center (CTRC)</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2009</study_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Neoplasms</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Breast</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Ovary</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Pancreatic</keyword>
  <keyword>Lung</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non Small Cell Lung</keyword>
  <keyword>Prostate</keyword>
  <keyword>Gastric</keyword>
  <keyword>Head and Neck</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

